Cassava Sciences (SAVA) has entered into an agreement with Yale University for a license to intellectual property rights, including an exclusive license to an issued US method of treatment patent for simufilam as a potential treatment for seizures related to rare neurodevelopmental disorders including tuberous sclerosis complex. Simufilam is Cassava’s proprietary small molecule drug candidate that targets filamin A.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue